by Paul Krzyzanowski | Sep 10, 2013
. Earlier this summer I had the fortunate opportunity to speak with Dr. Michael West, of BioTime, and pick his brain on various aspects of the stem cell industry, what it’s faced, and where it might go. It was a perfect follow up to my post in March that explored...
by Sasha (Alexandra) Lisovsky | Aug 13, 2013
. I was very fortunate to win a CCRM (Centre for Commercialization of Regenerative Medicine) scholarship to attend the 6th Annual “Business of Regenerative Medicine: From Stem Cells to the Market Place” at Case Western Reserve University in Cleveland, Ohio. The focus...
by David Brindley | Jul 9, 2013
. At the close of ISSCR2013, I left Boston bathed in an ochre sunset, and settled on a plane to reflect on what my most unexpected learning had been. My plane was bound not for home (London), but for Istanbul, where the TERMIS meeting was about to begin. As far as I’m...
by Paul Krzyzanowski | Jun 6, 2013
GMO soybeans might have lessons for cell patents. Photo: Philip Dean via Flickr . At first glance, you wouldn’t think that a 76-year old soybean farmer from Indiana would have something in common with microbiologists, but Vernon Hugh Bowman brought back memories of my...
by Paul Krzyzanowski | Apr 16, 2013
. Last week I posted a summary of the first half of a full day Communications for Scientists workshop organized by the Stem Cell Network. This post picks up where I left off, with a description of a “Dragon’s Den” style pitch session intended to introduce trainees to...
by Paul Krzyzanowski | Mar 13, 2013
[pullquote]In time, this purchase might make BioTime the company that Geron was supposed to be.[/pullquote]Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some...
Comments